Nightstar Files SEC Paperwork for Initial Public Offering

September 1, 2017: By Jon Swedien

Nightstar TherapeuticsNightstar Therapeutics Limited has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering in the US of its American depositary shares (ADSs) representing ordinary shares, the company announced Aug. 31.

Nightstar is a clinical-stage gene therapy company focused on novel one-time treatments for patients with rare inherited retinal diseases that would otherwise progress to blindness.

All shares to be sold in the offering will be offered by Nightstar, the company said.

The number of shares and price range have not been set, Nightstar said.

The company has applied to list its shares on the NASDAQ Global Market under the ticker symbol “NITE.”

Nightstar expects its lead product candidate, NSR-REP1, to begin a Phase III trial for choroideremia in the the first half of 2018.

The company also has an ongoing Phase I/II clinical trial for NSR-RPGR, a proposed treatment for X-linked retinitis pigmentosa.

In addition, Nightstar has a Phase I/II clinical trial planned for late 2018 for a gene therapy candidate for an inherited form of macular dystrophy.

In June, Nightstar raised $45 million in a Series C financing.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023